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Background: Mesalamine has been used as the ﬁrst-line medi-
cation for the treatment of ulcerative colitis (UC). We directly
compared the efﬁcacy and safety of two different mesalamine for-
mulations in the maintenance of remission in patients with UC.
Methods: In a multicenter, double-blind, randomized study, 131
patients with quiescent UC were assigned to two groups: 65 to
receive a pH-dependent release formulation of mesalamine at 2.4
g/day (pH-2.4 g) and 66 to receive a time-dependent release for-
mulation of mesalamine at 2.25 g/day (Time-2.25 g). Both formu-
lations were administered three times daily for 48 weeks. The
primary endpoint was the proportion of patients without bloody
stools.
Results: In the full analysis set (n ¼ 130), the proportion of
patients without bloody stools was 76.9% in the pH-2.4 g and
69.2% in the Time-2.25 g, demonstrating the noninferiority of pH-
2.4 g to Time-2.25 g. No statistically signiﬁcant difference in time
to bloody stools was found between the two formulations (P ¼
0.27, log-rank test), but the time to bloody stools tended to be lon-
ger in pH-2.4 g compared to Time-2.25 g, and a similar trend was
observed with regard to the time to relapse. No differences were
observed between the safety proﬁles of the two formulations.
Conclusions: The pH- and time-dependent release of mesal-
amine formulations were similarly safe and effective. Interest-
ingly, the remission phase tended to be longer in the group that
received the pH-dependent formulation compared to the group
that received the time-dependent formulation (UMIN Clinical Tri-
als Registry, no. C000000289).
(Inﬂamm Bowel Dis 2010;16:1575–1582)
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U
lcerative colitis (UC) is a chronic disease characterized
by inﬂamed mucosa limited to the large intestine. The
etiology of UC has not yet been elucidated. The major
therapeutic approaches to UC include drug therapy and sur-
gery, and the goal is long-term control of the disease con-
dition in order to improve the patients’ quality of life
(QOL).
1,2 Various formulations of mesalamine, corticoste-
roids and immunosuppressants have been utilized to treat
UC. However, long-term treatment with oral mesalamine
has been the key approach to the treatment of patients with
UC, especially in the remission phase, because of its safety,
effectiveness and its potential for a decrease in the risk of
colorectal cancer.
3,4
Because mesalamine exerts its effect directly on the
inﬂamed mucosa, higher concentration of mesalamine in
the mucosa is required to attain a more pronounced effect.
However, since mesalamine is absorbed in the upper gas-
trointestinal tract,
5–7 many controlled-release formulations
of oral mesalamine, such as pH-dependent release and
time-dependent release formulations, have been developed
to enhance its effect. A time-dependent release formulation
coated with ethyl cellulose (Pentasa) gradually releases
mesalamine starting in the stomach,
7,8 whereas a pH-de-
pendent release formulation coated with Eudragit-S (Asa-
col) releases mesalamine in the distal ileum or colon, since
the coating dissolves at pH 7 or higher.
7–9
There has been no comparative study to assess the
clinical effects of the two formulations with different
release proﬁles, and thus little scientiﬁc evidence for
choosing one formulation over the other is currently
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ducted a double-blind, randomized, controlled study aimed
to clarify this issue, comparing the efﬁcacy and safety of
two types of release formulations in patients with UC in




We conducted the study in patients with quiescent
UC on the basis of two inclusion criteria: 1) outpatients
who were 16–64 years of age at the time of the informed
consent, and 2) patients who had quiescent UC deﬁned by
an UC disease activity index (UC-DAI) of 2 or less and a
bloody stool score of 0. The UC-DAI was originally devel-
oped by Sutherland et al.
10
The patients were excluded according to following cri-
teria: 1) corticosteroids (oral preparations, enemas, supposito-
ries, injections and/or remedies for hemorrhoidal diseases)
and/or cytapheresis within 14 days before the start of the
investigational drugs; 2) immunosuppressants within 90 days
before the start of the investigational drug; 3) any other
investigational drugs within six months before informed con-
sent (except the investigational drugs in a study for active
UC, UMIN Clinical Trials Registry, no. C000000288); 4) a
history of hypersensitivity to mesalamine or salicylate drugs,
severe cardiac disease, pulmonary disease and/or hematologi-
cal disease; 5) severe hepatopathy, severe nephropathy and/
or a malignant tumors; and 6) pregnant or lactating.
Ethical Considerations
This study was conducted according to the principles
of the Declaration of Helsinki after obtaining approvals
from the Institutional Review Board at each of the partici-
pating medical centers. Written informed consent was
obtained from all participants.
Study Drugs
The pH-dependent release mesalamine formulation
used in this study was a tablet coated with Eudragit-S (Asa-
col 400 mg tablet, Tillotts Pharma - AG, Ziefen, Switzer-
land, supplied by ZERIA Pharmaceutical, Tokyo, Japan).
The time-dependent release mesalamine formulation used in
this study was a tablet coated with ethyl cellulose (Pentasa
250 mg tablet, Nissin Kyorin Pharmaceutical, Japan). This
study was conducted using a double-dummy method.
Study Design
This double-blind, randomized, controlled study was
conducted at 50 centers in Japan. Treatment assignments
were balanced according to two patient demographics with
the use of a biased-coin minimization algorithm. The ﬁrst
was prior participation in a study of the same two mesal-
amine formulations in patients with active UC conducted
during the same period as the present study: UMIN Clini-
cal Trials Registry, no. C000000288 (Yes or No). The sec-
ond was the duration of the remission phase of UC (<2
years or  2 years). Balance within each medical center
was also taken into consideration. A person independent
from the study was in charge of the random allocation.
Four patients were assigned as a block as follows: 2 to a
group given the pH-dependent release mesalamine formula-
tion at 2.4 g/day (pH-2.4 g) and 2 to a group given the
time-dependent release mesalamine formulation at 2.25 g/
day (Time-2.25 g). The randomization code was sealed and
stored until the blind was removed.
At time of the informed consent, investigators evaluated
the background characteristics of patients. After an observa-
tion period of 3–14 days from the time of informed consent,
investigators assessed patients for their eligibility for enrol-
ment according to criteria previously described. At the assess-
ment for eligibility, the UC-DAI was calculated using a previ-
ously reported method.
11,12 The UC-DAI is the sum of the
mucosal appearance score (based on the colonoscopy ﬁndings
by reference to atlases of mucol appearance), stool frequency
score bloody stool score, and physician’s global assessment
score (stage 0, 1, 2, or 3). Each score was based on the
patients’ diary for the last three days. The area of the inﬂam-
mation was also determined by colonoscopy. Patients who
were judged as eligible were enrolled and assigned to investi-
gational drugs by a central registration center, and then admin-
istration was started. The investigational drugs were adminis-
tered three times daily for 48 weeks.
During the study, each patient recorded the condition
of their bloody stools, stool frequency and drug compliance
in their diary and visited the medical center every four
weeks. Each component of UC-DAI, except the mucosal
appearance score, was assessed at each visit.
11,12 Colono-
scopy was performed at 48 weeks or at withdrawal from
the study, and the mucosal appearance score at that time
was used to calculate UC-DAI. To evaluate safety, clinical
laboratory data and vital signs were checked at the time of
informed consent and every 12 weeks after enrolment (or
upon withdrawal). The presence or absence of adverse
events (AEs) and adverse drug reactions (ADRs) were
recorded by investigators at each visit.
Statistical Analysis
The primary endpoint was the proportion of patients
without bloody stools. The presence of bloody stools was
deﬁned as a bloody stool score of 1 or more. The principal
hypothesis was the noninferiority of pH-2.4 g to Time-2.25
g, using the proportion of patients without bloody stools.
Our hypothesis was veriﬁed by the following meth-
ods. The noninferiority of pH-2.4 g to Time-2.25 g was
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1576demonstrated if the lower limit of the 95% conﬁdence
interval (CI) was more than ‘‘ 10.0%’’ in the difference of
the proportion of patients without bloody stools between
the two groups (pH-2.4 g minus Time-2.25 g). In addition,
the superiority of pH-2.4 g over Time-2.25 g was demon-
strated if the lower limit of the 95% CI was more than
‘‘0.0%’’ in the difference of the proportion of patients with-
out bloody stools between the two groups. The secondary
endpoints were time to bloody stools, proportion of patients
without relapse, time to relapse and decrease in UC-DAI.
In this study, relapse was deﬁned as a bloody stool score
of 1 or more and UC-DAI of 3 or more. Survival values of
the time to events were determined by the Kaplan–Meier
method with time to bloody stools and time to relapse. The
functions were compared by the log-rank test and the haz-
ard ratio (HR) of pH-2.4 g to Time-2.25 g and the 95% CI
were calculated. A statistically signiﬁcant difference was
demonstrated when the 95% CI of the difference between
the groups did not include zero with regard to proportions
of patients without relapse and the decrease in UC-DAI. In
the safety endpoints, the numbers of patients with AEs and
patients with ADRs were analyzed by Fisher’s exact test.
Unless otherwise speciﬁed, differences at a ¼ 0.05
(two-sided) and P < 0.05 were considered statistically sig-
niﬁcant. The statistical analyses were conducted by ZERIA
Pharmaceutical, Japan, based on statistical advice of an
expert independent of this study.
The number of patients required to determine the
hypotheses was estimated to be 57 at a ¼ 0.05 (two-sided),
b ¼ 0.1 and D ¼ 10% when the proportion of patients with-
out bloody stool was 65% in pH-2.4 g and 45% in Time-
2.25 g, respectively. According to the above estimations, we
decided to enroll at least 60 patients in each group consider-
ing the patients excluded from the analysis set.
The full analysis set (FAS) consisted of all partici-
pants except those who had not taken even one tablet of
the investigational drug, those who did not comply with
Good Clinical Practice (GCP) and those whose data were
missing at the efﬁcacy endpoint. The per protocol set
(PPS) consisted of the FAS except those who did not fulﬁll
the inclusion criteria, those who met the exclusion criteria,
those who received forbidden drugs and those whose drug
compliance was less than 75%. Concerning the withdrawal
cases, their adoption was to be decided before the bind was
removed. The statistical analysis of efﬁcacy was performed
primarily based on data from the FAS followed by compar-
ison with those in the PPS. The dataset for safety consisted
of all participants except those who had not taken even one
tablet of the investigational drug and those who did not
comply with GCP.
Independent Image Assessment Committee
We established an image assessment committee inde-
pendent from the investigators to ensure the reliability of
the mucosal appearance scores, and each of the three mem-
bers of the committee blindly and independently scored the
mucosal appearance by examining photos provided by the
investigators. When the score obtained from all three mem-
bers was the same, that score was regarded as a judgment
by the committee. If the scores were different, the
FIGURE 1. Enrolment, randomization, and follow-up of the study patients.
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consensus. When the judgment by the committee and the
evaluation by the investigators were the same, it was
deﬁned as an agreement case.
RESULTS
Patient Demographics
Investigators obtained informed consent from 143
patients during the period from January to September 2006
and completed the ﬁnal follow-up in September 2007 (Fig.
1). Of the 143 patients from whom consent was obtained, a
total of 131 patients were assigned to the two groups (pH-
2.4 g, 65; Time-2.25 g, 66). All of the 131 patients took
the drug at least once. Drug compliance was greater than
75% in every patient.
A total of 34 patients (pH-2.4 g, 16; Time-2.25 g,
18) withdrew from the study. The most frequent reason for
withdrawal was relapse of UC based on the discontinuation
criteria of a bloody stool score of 1 or more and UC-DAI
of 3 or more (pH-2.4 g, 10; Time-2.25 g, 13), and the sec-
ond most common reason was the occurrence of AEs (pH-
2.4 g, 1; Time-2.25 g, 3).
There were 130 patients in the FAS (pH-2.4 g, 65;
Time-2.25 g, 65) and 126 patients in the PPS (pH-2.4 g,
64; Time-2.25 g, 62). The results were very similar when
the data were analyzed according to the FAS or PPS.
Therefore, the result analyzed according to the FAS will be
shown at the following. We did not perform adjustments
for demographic factors because patient demographics in
all groups were similar (Table 1).
Efficacy
The proportion of patients without bloody stools was
76.9% in pH-2.4 g and 69.2% in Time-2.25 g (Table 2).
The difference between the two groups was 7.7% (95% CI:
 7.4, 22.8), and the lower limit of CI was more than
‘‘ 10.0%’’, the critical value for demonstration of predeter-
mined noninferiority.
The HR for time to bloody stools was 0.690 (95%
CI: 0.353, 1.350, Fig. 2). There was no signiﬁcant differ-
ence in the results of the log-rank test between the two
groups (P ¼ 0.27), but the time to bloody stools tended to
be longer in pH-2.4 g in comparison with Time-2.25 g.
The proportion of patients without relapse was 80.0% in
pH-2.4 g and 79.7% in Time-2.25 g (Table 2). The time to
relapse also was prolonged in pH-2.4 g compared to Time-
2.25 g, in a similar manner to the time to bloody stools
(Fig. 2), but the difference was not statistically signiﬁcant
(P ¼ 0.79). The decrease in UC-DAI at the ﬁnal assess-
ment was  0.8 in pH-2.4 g and  0.9 in Time-2.25 g,
respectively, and the difference between the two groups
was not signiﬁcant (Table 2).
Table 3 summarizes the relationship between the
patients with bloody stools and the patients with relapse. In
pH-2.4 g, 13 of the 15 patients with bloody stools experi-
enced a relapse. In Time-2.25 g, 13 of the 19 patients with
bloody stools experienced a relapse (one of the 20 patients
with bloody stools was excluded for a missing mucosal
appearance score).
Reliability of the Mucosal Appearance Scores
Table 4 summarizes the proportion of agreement in
judgments by the image assessment committee and the
evaluations by the investigators. The proportion of agree-
ment was 69.3%, and Cohen’s j coefﬁcient was 0.486.
Safety
There were no statistically signiﬁcant differences
between the two groups regarding AEs and ADRs (Table
5). Serious AEs consisted of aggravation of UC in 3
patients (pH-2.4 g, 2; Time-2.25 g, 1). The investigators
did not rule out a causal relationship to the drug in 1
patient in the pH-2.4 g group.
DISCUSSION
Previous randomized controlled studies showed that
the pH- and time-dependent release formulations of


















 54 1 2 8
Inﬂamed areas (no. of patients)
Proctitis-type 23 27
Others 42 38
Years of present remission
(no. of patients)
<24 4 4 6
 22 1 1 9
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cebo.
13,14 However, the criteria for clinical relapse differed
in the individual studies. Moreover, the studies employed
different administration periods and doses, and such differ-
ences made it impossible to compare their results. In the
present study we demonstrated the noninferiority of the
pH-dependent release formulation of mesalamine to its
time-dependent release formulation. The results of the pres-
ent study were meaningful because this study was con-
ducted with concurrent control.
Sutherland et al
10 found that decreases in bloody
stool score and in the mucosal appearance score paralleled
symptomatic improvement. In our study, UC-DAI increased
in the patients with bloody stools in both groups, whereas
there was little change in UC-DAI in the patients without
bloody stools in either group (Table 3). These results
FIGURE 2. Time to bloody stools and time to relapse. The graphs show survival curves in patients without bloody stools (A)
and without relapse (B). The number of patients maintained on each drug is shown below the graph.




(n ¼ 65) Difference
Bloody stools
No. of patients 65 65
Presence 15 20
Absence 50 45
Absence (%) 76.9 69.2 7.7
(95% CI) (64.9, 86.4) (56.6, 80.0) ( 7.4, 22.8)
Relapse
No. of patients 65 64
Presence 13 13
Absence 52 51
Absence (%) 80.0 79.7 0.3
(95% CI) (68.3, 88.8) (67.8, 88.7) ( 13.5, 14.1)
Decrease in UC-DAI
No. of patients 57 59
Mean  0.8  0.9 0.1
SD (95% CI) 2.4 ( 1.4,  0.2) 2.3 ( 1.4,  0.3) ( 0.7, 0.9)
In the comparison of the frequency of relapse, one patient was excluded because the mucosal appearance data were missing in Time-2.25 g. Decrease in
the UC-DAI was calculated from the scores at the initial and ﬁnal assessments. The data of 14 patients (pH-2.4 g, 8; Time-2.25 g, 6) had to be excluded
from the analysis because the mucosal appearance data were missing.
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relapse (based on the clinical activity index) and bloody
stools (based on the patient interviews). Therefore, we con-
sider the presence or absence of bloody stools to be a use-
ful predictor of clinical relapse in patients with UC in the
remission phase.
Because UC is characterized by repeated relapses and
remissions, the goal of treatment is to maintain the remis-
sion phase as long as possible in order to maintain the
QOL of the patient.
1,2 The prolongation of the remission
phase is, therefore, an important indicator of the clinical ef-
ﬁcacy of UC therapy. In the present study the time to
bloody stools and the time to relapse tended to be longer
in the group treated with the pH-dependent release formu-
lation, but the difference was not signiﬁcant (Fig. 2). We
assume that the drug-release mechanism described previ-
ously was responsible for the improvement in symptoms
seen with the pH-dependent release formulation in this
TABLE 3. Relapse and Decrease in the UC-DAI According to Whether Patients Had Bloody Stools
pH-2.4 g (n ¼ 15) Time-2.25 g (n ¼ 20) Difference
A
Patients with bloody stools
Relapse No. of patients 15 19
Presence 13 13
Absence 2 6
Absence (%) 13.3 31.6
Decrease in UC-DAI No. of patients 10 16
Mean  5.0  3.1  1.9
SD (95% CI) 2.4 ( 6.7,  3.3) 3.1 ( 4.7,  1.5) ( 4.2, 0.4)
pH-2.4 g (n ¼ 50) Time-2.25 g (n ¼ 45) Difference
B
Patients without bloody stools
Relapse No. of patients 50 45
Presence 0 0
Absence 50 45
Absence (%) 100.0 100.0
Decrease in UC-DAI No. of patients 47 43
Mean 0.1 0.0 0.1
SD (95% CI) 1.2 ( 0.2, 0.4) 1.1 ( 0.3, 0.3) ( 0.3, 0.5)
Decrease in UC-DAI was calculated from the scores at the initial and ﬁnal assessments.
A: Comparison of the frequency of relapse and the decrease in the UC-DAI in the patients with bloody stools. In judgments of the presence or absence of
relapse, the data of one patient in 20 patients with bloody stools in Time-2.25 g was excluded because the mucosal appearance data were missing.
B: Comparison of the frequency of relapse and the decrease in UC-DAI at the ﬁnal evaluation in the patients without bloody stools.
[correction made to table after initial online publication].
TABLE 4. Agreement Between Evaluations by the Investigators and Judgments by the Image Assessment Committee
n ¼ 114
Evaluations by the Investigators
Total 012 3
Judgments by committee 0 41 7 0 0 48 Proportion of agreement (%) 69.3
11 33 41 00 5 7
2034 2 9
3 0 0 0 0 0 Cohen’s j coefﬁcient 0.486
Total 54 44 14 2 114
Proportion of agreement (%) ¼ (number of agreement cases) / (number of cases conﬁrmed by colonoscopy)   100
In this trial, 131 patients were allocated to an intervention. The data of 16 patients had to be excluded from the analysis because the mucosal appearance
score was missing, and the data of one patient had to be excluded from the analysis because of a GCP violation.
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able because of higher mesalamine concentrations in the
mucosa. An inverse correlation between the UC-DAI and
mucosal mesalamine concentration has been reported in
patients without bloody stools.
15 Accordingly, the pH-de-
pendent release formulation may deliver an adequate
amount of mesalamine to the inﬂamed area and effectively
suppress symptom aggravation for longer periods.
Comparison of the judgments by the image assess-
ment committee and the evaluations by the investigators
revealed a consistency of  70% (Table 4). The Baron
score is an endoscopic index that is popular in evaluating
the severity of the mucosal appearance.
16 Hirai and Mat-
sui
17 reported a relationship between the scores by two
raters who employed the Baron score. In their study the pro-
portion of agreement and j coefﬁcient between two raters
were 51% and 0.31, respectively, but their coefﬁcient was
lower compared to our study. In the Hirai and Matsui study,
8.7% of all patients observed two degrees of difference in
the scores between two raters. On the other hand, in our
study there were no cases showing two degrees of differ-
ence. Thus, we assumed that the interobserver variation
among the investigators was well controlled in our study.
There were no differences in the safety proﬁles
between the groups (Table 5). The proportion of patients
who experienced AEs was high in our study, at  95% in
each group. This high proportion is likely attributable to
the long administration and long follow-up periods. Addi-
tionally, all of the frequent events shown in Table 5 were
mild, and there were no severe events causally related to
either drug. Thus, no particular safety issue regarding long-
term use of either mesalamine formulation was raised in
this study. The ﬁnding is consistent with the current con-
sensus that oral mesalamine is a safe and effective treat-
ment for UC.
In summary, this is the ﬁrst study to directly compare
the efﬁcacy and safety of pH- and time-dependent mesal-
amine formulations for the maintenance of remission in
patients with UC. The results show that the pH-dependent
release formulation of mesalamine evaluated in this study
is as effective as the time-dependent formulation. In addi-
tion, the pH-dependent release formulation tended to pro-
long the duration of the remission phase. These results
imply that treatment with the pH-dependent release formu-
lation is capable of improving the QOL of patients with
UC in the remission phase. However, further study is
needed to clarify precisely how the drug-release mecha-
nism contributes to the prolongation of the remission
phase. Once it is clariﬁed, it may be feasible to select the
optimal mesalamine formulation for each patient in accord-
ance with the individual patient’s disease phenotype.
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